Research Analysts Set Expectations for Sanofi Q2 Earnings

Sanofi (NASDAQ:SNY - Free Report) - Research analysts at Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for Sanofi in a research report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn $0.94 per share for the quarter, down from their prior forecast of $0.99. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's FY2025 earnings at $4.53 EPS, FY2026 earnings at $4.96 EPS, FY2027 earnings at $5.08 EPS, FY2028 earnings at $5.48 EPS and FY2029 earnings at $6.01 EPS.

SNY has been the topic of several other research reports. Morgan Stanley set a $56.00 price objective on Sanofi in a report on Monday, June 2nd. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. The Goldman Sachs Group began coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Three analysts have rated the stock with a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $61.50.

Sanofi Price Performance

Shares of NASDAQ SNY traded down $0.73 during mid-day trading on Wednesday, hitting $48.61. 1,207,445 shares of the stock traded hands, compared to its average volume of 2,327,496. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a market cap of $119.21 billion, a PE ratio of 17.36, a price-to-earnings-growth ratio of 1.12 and a beta of 0.48. The firm has a 50 day simple moving average of $50.05 and a two-hundred day simple moving average of $52.08.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter last year, the business posted $1.78 EPS. Sanofi's revenue for the quarter was down 11.0% on a year-over-year basis.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were given a $2.0369 dividend. The ex-dividend date of this dividend was Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio (DPR) is 57.14%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SNY. Brighton Jones LLC increased its position in Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after buying an additional 1,869 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Sanofi by 8.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company's stock valued at $7,328,000 after buying an additional 12,440 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Sanofi in the 4th quarter valued at about $402,000. Amundi increased its position in Sanofi by 11.1% in the 4th quarter. Amundi now owns 630,063 shares of the company's stock valued at $31,017,000 after buying an additional 63,195 shares in the last quarter. Finally, Wealthfront Advisers LLC bought a new stake in Sanofi during the 4th quarter worth approximately $1,908,000. 14.04% of the stock is owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.